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KashmirBackground: Recently, three coding polymorphisms in X-ray cross complementing gene 1 (XRCC1) have
been identified; with probable effect on DNA repair capacity and thus modulation of cancer susceptibil-
ity. Moreover, association of these polymorphisms with the cancer risk are reported to be population
dependent. Therefore, in this case control study we aimed to investigate the polymorphism at codon
194 (Arg to Trp) in XRCC1 gene and the possible association of its polymorphic genotypes with skin can-
cer in the ethnically different population of Kashmir.
Aim: To study if there is any possible association of Arg194Trp XRCC1 polymorphism with risk of devel-
oping skin cancer in ethnically different Kashmir population.
Subjects and methods: For this study 68 skin cancer patients and 60 healthy controls, matched for age and
gender were recruited. PCR-RFLP followed by statistical analysis was employed to check for the C194T
polymorphism and its possible association with the skin cancer risk in the population.
Result: An insignificant association among skin cancer patients with respect to the wild (Arg/Arg) versus
variant (Trp/Trp) genotypes (OR = 0.34, 95% CI = 0.10–1.05, p = 0.06) was observed. However, individually
homozygous and heterozygous variant alleles were observed to be associated with risk of developing skin
cancer. As far as, individual allelic ratio among cases and controls is concerned Trp allele of codon194
showed a remarkably high frequency in cases (67.7% vs. 32.3%) in comparison with controls
(OR = 1.94, 95% CI = 1.22–3.0, p = 0.004).
Discussion: These findings suggest that the combined homozygous and heterozygous variants of each
codon and the 194Trp allele are associated with the disease, however when genotypes were compared
individually, the association turned out to be insignificant.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Skin cancer, like any other cancer, involves unaccountable
growth of skin cells, having ability to invade or spread to other
parts of body. It occurs when unrepaired DNA damage to skin cells
(most often caused by ultraviolet radiation from sunshine) triggers
mutations, or genetic defects, that lead the skin cells to multiply
rapidly and form malignant tumors [1]. Skin cancers are now rep-
resenting a major public health concern with nearly 15,000 deaths,
3.5 million new cases, and more than 3 billion dollars a year in
medical costs in the United States alone [2]. In Kashmir, skin can-
cers ranks sixth among all cancers in males, corresponding to 3.46%of all cancers for the year 2000–2012 [3]. The major external cause
of melanoma, as with all skin cancers, is sun exposure, but this is
heavily modified by other personal risk factors such as the number
and type of benign melanocytic naevi or moles (lesions of pigment
forming skin cells), the character and intensity of skin pigmenta-
tion, and skin sensitivity to sunlight [4]. Extensive epidemiological
and experimental data suggests that it is Ultraviolet (UV) radiation
which is an important environmental carcinogen involved in the
initiation and progression of skin cancer [5]. Currently, it is esti-
mated that UV exposure is associated with 65% of melanoma cases
and 90% of non-melanoma skin cancers, including basal cell carci-
noma and squamous cell carcinoma [6]. Direct absorption of UVA
radiations at short wavelengths (280–320 nm) cause DNA damage
in the form of cyclobutane pyrimidine dimmers and generates
pyrimidine photoproducts [7], while as UVB at short wavelengths
(320–400 nm) causes single-stranded breaks, DNA-protein cross
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age to DNA [8]. Cells respond to this damage through the activation
of various DNA repair pathways, including the base excision repair
(BER) pathway.
DNA repair gene X-ray repair cross-complementing group-1
(XRCC1), the member of the base excision repair pathway, corrects
defective DNA strand-break repair and sister chromatid exchange
following treatment with ionizing radiation and alkylating agents
[9]. Polymorphisms in several DNA repair genes have been
described affecting DNA repair capability and modulate cancer sus-
ceptibility by means of gene-environment interactions [10] and
studies have been reported that link it with the risk of various
types of cancer including lung cancer [11], squamous cell carci-
noma (SCC) of head and neck [12], pancreatic adenocarcinoma
[13], bladder cancer [14], and breast cancer [15]. At least three
genetic variants have been recognized in the multi-protein inter-
acting regions of DNA repair gene XRCC1 gene that result in amino
acid changes from Arginine (Arg) to Tryptophan (Trp) at codon 194
(Arg/Trp), from Arginine (Arg) to Histidine (His) at codon 280 (Arg/
His) and from Arginine (Arg) to Glutamine (Gln) 399 (Arg/Gln),
respectively, thereby weakening the DNA repair capacity [16].
While XRCC1 has been seen to be important in DNA repair and a
number of studies have been carried out regarding the role of poly-
morphic forms of XRCC1 in susceptibility to cancer, the effect of
genetic polymorphisms on the risk of disease may vary from one
population to the others due to the differences of the frequencies
and types of polymorphisms as well as the exposed carcinogens
in a studied population [17–19]. Kashmir valley is distinct from
rest of India as far as its geography, climate, social and dietary
habits are concerned. Till date no data exists, to our knowledge,
on the association of XRCC1 polymorphism in susceptibility to skin
cancer among Kashmiri population. This study is therefore the first
investigative effort in describing the association between XRCC1
polymorphism and skin cancer susceptibility.2. Subjects and methods
2.1. Sample selection and collection
After obtaining the necessary ethical clearance from the institu-
tional ethics committee, 68 histopathologically confirmed skin
cancer patients were recruited for the study at the Department
of Dermatology, Shri Maharaja Hari Singh Hospital, Srinagar, Kash-
mir. The recruited subjects had no earlier history of any malig-
nancy and had not received any type of pre-operative chemo or
radiotherapy. Of the 68 recruited cases, 40 were male and rest
females. For control group, 60 healthy individuals were recruited,
of which 37 were males and 23 females. The subjects selected as
controls had no family history of any malignancy. About 3 ml of
peripheral blood was collected from each subject in sterilized vials
coated with EDTA (0.5 M; pH-8.0) and stored at 80 C for further
analysis. All the necessary information for the study was collected
from the cases and the control subjects and properly documented.
The cases and control subjects were age and gender matched.Table 1
PCR cycling parameters.
Steps Temperature C Time Number of cycles
Initial Denaturation 95 5 min 1
Denaturation 95 30 s 30
Annealing 58 40 s
Extension 72 30 s
Final extension 72 5 min 12.2. Whole genomic DNA isolation
Whole genomic DNA was isolated from the blood cells by
phenol-chloroform method. The quality of the isolated genomic
DNA was examined by gel electrophoresis using 1% agarose gel.
Gel was visualized by a Gel doc system (Endura) under UV light.
The ratio of A260/A280 was also calculated and the DNA sample
for which the ratio was 1.7–1.9 was considered for the future
use. The DNA was stored at 4 C for a short time but the vials were
kept at 20 C for longer duration storage.2.3. PCR amplification
The isolated whole genomic DNA was subjected to Polymerase
Chain Reaction (PCR) amplification in automated thermal cycler
(eppendorf) to amplify the desired target i.e. exon 6, codon 194
of XRCC1 gene, using the pair of primers (Forward primer: 50-GCC
CCGTCCCAGGTA-30 and Reverse primer: 50-AGCCCCAAGACCCTTT
CACT-30). PCR was performed in total volume of 25 ll volume
under the following set of conditions (Table 1):2.4. Restriction digestion
The PCR product of 491 bp was digested with specific restriction
enzymes for detecting the codon 194 polymorphism of the XRCC1
gene. The standard protocol for restriction digestion was used.
Ten microliters of the PCR products were digested separately with
5 units (0.5 ll) of MspI (Fermantas, USA). The reaction mixture
included 2 ll of 10x buffer and 18 ll of Milli Q water. The mixture
was incubated at 37 C for 24 h. The products were then resolved
on 3% agarose gels. DNA molecular weight marker of 100 bp was
used to assess the size of the PCR–RFLP (Restriction fragment
length polymorphism) products.2.5. Statistical analysis
Results were statistically analyzed and data was expressed as
mean ± SD. Allele and genotype frequencies were compared
between groups using the v2-test. The association between XRCC1
genotype and the risk of Skin cancer was estimated by calculating
odds ratio (OR) and their 95% confidence intervals (95% CI). A P
value of <0.05 was used as a criterion for statistical significance.
For the analysis, statistical software Graph Pad Prism version 5.0
was used.3. Results
3.1. General characteristics of study population
Present case-control study included 68 histopathologically con-
firmed skin cancer cases and 60 healthy controls, matched with
respect to age and gender. General characteristics of the skin can-
cer patients and controls are given in Table 2. Out of 68 cases, 40
were males with mean age (51.12 ± 7.8) and 28 were females with
mean age (50.85 ± 6.79) years. As far as age is concerned, 41
(60.3%) were found above 50 years of age and 27 (39.7%) were
found below 50 years of age. Similarly, in 60 healthy controls, it
was found that 37 were males with mean age (50.08 ± 8.01) and
23 were females with mean age (51.08 ± 8.23) years. Out of these
controls, 35 (58.3%) were found above 50 years of age while as
25 (41.7%) were found below 50 years of age. Of all the regions
of the Kashmir division, 35 (51.5%) cases turned out from the urban
area and 33 (48.5%) were from rural areas, while as in case of con-
trols 31 (51.6%) turned out from urban areas and 29 (48.4%) were
from rural areas.
Fig. 2. Representative gel picture showing RFLP analysis of PCR product on 3%
agarose gel. Lane M is the 100 bp DNA molecular weight marker. Lane no. 1 and 6
shows C/C wild genotype (292 bp and 174 bp). Lane no. 2 and 5 denotes T/T
homozygous mutants (313 bp and 174 bp). Lane no. 3 and 4 represents C/T
heterozygous variant respectively (313 bp, 292 bp and 174 bp).
Table 2
General characteristics of study population.
Demographic features Cases (n = 68) Controls (n = 60)
Age (mean ± SD) (mean ± SD)
Males 51.12 ± 7.8 50.08 ± 8.01
Females 50.85 ± 6.79 51.08 ± 8.23
Gender
Male 40 (58–8%) 37 (61.5%)
Female 28 (41.2%) 23 (38.5%)
Residence
Urban 35 (51.5%) 31 (51.6%)
Rural 33 (48.5%) 29 (48.4%)
Family history of cancer
Yes 17 (25%) 9 (15%)
No 51 (75%) 51 (85%)
X-ray radiation exposure
Yes 49 (72%) 38 (63.3%)
Never 19 (28%) 22 (36.7%)
n = no of subjects, SD = standard deviation.
R. Maqbool et al. / The Egyptian Journal of Medical Human Genetics 19 (2018) 91–95 933.2. XRCC1 genotyping
Whole genomic DNA from 128 subjects was subjected to PCR
amplification as per the protocol given in methods section. The
PCR amplification of the desired target gene generated 491 bp pro-
duct (Fig. 1) which was then subjected to restriction digestion,
using Msp1 restriction enzyme. The product was then resolved
on 3% agarose gel. The wild type C (Arg) allele for codon 194 was
determined by the presence of a band at 292 bp, while the mutant
T (Trp) allele was determined by the presence of a band at 313 bp
(indicative of the absence of the MspI cutting site). In addition to
these bands, a 174 bp band, resulting from an additional invariant
cutting site for MspI in the 491 bp amplified fragment (codon 194)
is always present and serves as internal control for complete MspI
digestion. For homozygous wild type C/C (Arg/Arg), two bands
292 bp and 174 bp were identified, while as for heterozygous vari-
ant allele C/T (Arg/Trp), three bands 313 bp, 292 bp and 174 bp
were identified. Similarly for homozygous mutant T/T (Trp/Trp),
two bands 313 bp and 174 bp were identified. The digestion result
of this SNP is shown in Fig. 2. The three genotypes, C/C, C/T and T/T
are represented by the frequency of 52.99%, 29.4% and 17.6% inFig. 1. Representative gel picture showing XRCC1 exon 6 Amplicon on 2% agarose
gel. Lane M contains 50 bp DNA ladder. Lane 1–10 represent 491 bp amplicon of
exon 6.cases where as in controls these are represented by the frequency
of 73.33%, 18.3% and 8.4%, respectively (Table 3). When the allelic
frequencies were compared, wild type Arginine (C allele) was pre-
sent in 67.7% of cases where as the mutant Tryptophan (T) allele
was present in 32.3% of cases as compared to the 82.5% of Arginine
and 17.5% of Tryptophan in controls (Table 3). The tryptophan
allele was significantly associated with the risk of skin cancer in
cases as compared to controls.3.3. Comparison of XRCC1 genotypic frequency with respect to age and
gender of the study subjects
When XRCC1 genotypic frequency was stratified for age, below
and greater than 50 years (Tables 4 and 5), no significant associa-
tion was found when compared between cases and controls. Sim-
ilarly, when comparing the genotypic frequency among the
males and females, again no significant association was found with
the risk of developing skin cancer among cases as compared to
controls (Tables 6 and 7).4. Discussion
There is increasing evidence that genetic variation leads to dif-
ferent DNA repair capacities in the human population, hence such
common polymorphisms can play a major role in an individual’s
genetic susceptibility to cancer [20]. In mammalian cells four dif-
ferent DNA repair mechanisms have been identified: base excision
repair (BER), nucleotide excision repair (NER), double-strand break
repair and mismatch repair [21]. The BER pathway has a primary
role in the repair of oxidative base lesions such as 8-
hydroxyguanine, formamidopyrimidines, and 5-hydroxyuracil
[22] produced by methylation, oxidation or reduction by ionizing
radiation or oxidative damage [23]. BER pathway serves as an
important gladiator against DNA damage, which could lead to can-
cer, resulting from many factors, including altered metabolism,
reactive oxygen species, and methylating and deaminating agents
[24]. One such candidate gene involved in the base excision repair
pathway is the X-ray repair cross-complementing group1 gene or
XRCC1 gene. Mutations in XRCC1 gene may lead to decrease or loss
of its DNA repair capacity and confer the variation in susceptibility
to diverse malignant tumors among individuals [16]. About sixty
validated single nucleotide polymorphisms (SNPs) in the XRCC1
gene have been identified till date among which three affect the
coding region of the gene namely codon 194 (Arg/Trp), 280
Table 3
Genotypic and allelic frequencies of XRCC1 gene codon 194 among cases and controls and their association with risk of skin cancer.
Gene Variants Cases n = 68 Controls n = 60 v2 OR (95% CI) p value
XRCC1 (codon 194) C to T C/C (Arg/Arg) 36 (52.94%) 44 (73.3%) 1 Referent
C/T (Arg/Trp) 20 (29.4%) 11 (18.3%) 3.4 0.45 (0.19–1.0) 0.09
T/T (Trp/Trp) 12 (17.6%) 5 (8.4%) 3.67 0.34 (0.10–1.05) 0.06
C 92 (67.7%) 99 (82.5%) 1 Referent
T 44 (32.3%) 21(17.5%) 8.18 1.94 (1.22–3.0) 0.004
C/T + T/T 32 (47%) 16 (26.7%) 5.66 0.4 (0.19–0.86) 0.02
n = no. of subjects. OR (odds ratio) calculated at 95% Confidence Interval (CI). p-value (two –sided) Pearson v2 chi square test. p < 0.05 is considered to be significant.
Table 4
Genotypic frequencies of XRCC1 gene codon 194 among cases and controls stratified for below 50 years age.
Gene Variants Cases (n = 27) Controls (n = 25) v2 OR (95% CI) p value
XRCC1 (codon 194) C to T C/C 13 (48.2%) 16 (64%) 1 Referent
C/T 9 (33.3%) 7 (28%) 0.54 0.63 (0.18–2.16) 0.54
T/T 5 (18.5%) 2 (8%) 0.32 (0.05–1.95) 0.40
n = no. of subjects. OR (odds ratio) calculated at 95% Confidence Interval (CI). p-value (two-sided) Pearson v2 chi square test. p < 0.05 is considered to be significant.
Table 5
Genotypic frequencies of XRCC1 gene codon 194 among cases and controls stratified for above 50 years age.
Gene Variants Cases (n = 41) Controls (n = 35) v2 OR (95% CI) p value
XRCC1 (codon 194) C to T C/C 23 (56.1%) 28 (80%) 1 Referent
C/T 11 (26.8%) 4 (11.4%) 3.7 0.29 (0.08–1.06) 0.07
T/T 7 (17.1%) 3 (8.6%) 0.35 (0.08–1.51) 0.18
n = no. of subjects. OR (odds ratio) calculated at 95% Confidence Interval (CI). p-value (two-sided) Pearson v2 chi square test. p < 0.05 is considered to be significant.
Table 6
Genotypic and allelic frequencies of XRCC1 gene among cases and controls stratified for males.
Gene Variants Cases (n = 40) Controls (n = 37) v2 OR (95% CI) p value
XRCC1 (codon 194) C to T C/C 22 (55%) 28 (75.7%) 1 Referent
C/T 11 (27.5%) 6 (16.2%) 2.18 0.42 (0.13–1.34) 0.16
T/T 7 (17.5%) 3 (8.1%) 0.33 (0.07–1.45) 0.17
n = no. of subjects. OR (odds ratio) calculated at 95% Confidence Interval (CI). p-value (two-sided) Pearsons v2 chi square test. p < 0.05 is considered to be significant.
Table 7
Genotypic and allelic frequencies of XRCC1 gene among cases and controls stratified for females.
Gene Variants Cases (n = 28) Controls (n = 23) v2 OR (95% CI) P value
XRCC1 (codon 194) C to T C/C 14 (50%) 16 (69.6%) 1 Referent
C/T 9 (32.2%) 5 (21.7%) 1.19 0.48 (0.13–1.79) 0.34
T/T 5 (17.8%) 2 (8.7%) 0.35 (0.07–2.09) 0.40
n = no. of subjects. OR (odds ratio) calculated at 95% Confidence Interval (CI). p-value (two-sided) Pearsons v2 chi square test. p < 0.05 is considered to be significant.
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acid changes may alter XRCC1 function and may have an impact on
individual susceptibility to the development of cancers [26] .There
are previous reviews and meta-analyses that have been discussed
the association between XRCC1 polymorphisms and the risk of
developing cancer [27,28], but not skin cancer specifically. Even
though, several epidemiological studies have explored the rela-
tionship between XRCC1 polymorphisms and the development of
melanoma, basal cell carcinoma, and squamous cell carcinoma,
these studies have reached inconsistent conclusions on whether
any XRCC1 genetic variant could serve as a biomarker for skin can-
cer, with some studies showing an association [29,30] and some
studies failing to show any association [31,32]. There is another
study which reports that the Arg194Trp (C to T base change) vari-
ant increases the risk of basal cell carcinoma at sun-exposed sites
in a Japanese population [33].
In our case-control study, the overall association between the
XRCC1 Arg194Trp polymorphism and the skin cancer was foundto be insignificant (OR = 0.34, 95% CI = 0.10–1.05, p = 0.06)
(Table 5). On combining the homozygous and heterozygous vari-
ants of each codon, the variants seemed to be at a relatively higher
risk of developing skin cancer, and it was found statistically signif-
icant (OR = 0.4, 95% CI = 0.19–0.86, p = 0.02). We also assessed the
individual allelic frequencies among cases and controls, the T (Trp)
allele of codon194 showed a remarkably high frequency in cases
(67.7% vs. 32.3%) in comparison with controls (OR = 1.94, 95%
CI = 1.22–3.0, p = 0.004), this also showed a statistically significant
result. In this population-based case control study, we also
observed that most of the cases belong to the age group of over
50 years. Similarly while comparing gender we observed that
males are more affected than females. However, while assessing
the relationship between the genders across the genotypes of
XRCC1 Arg194Trp polymorphism, no statistically significant associ-
ation was observed. Moreover we also observed insignificant asso-
ciation of Arg194Trp polymorphic variants across various age
groups of the study subjects. The divergence in results from
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tion in carcinogenic exposure and ethnic origin of the studied pop-
ulation [17,18,34]. Since carcinogenesis is a complex process and
inter related pathways of biological response to DNA damage exist
involving multiple genetic mechanisms, therefore such inconsis-
tency in results among different populations can be attributed to
the fact that polymorphism might have multiple effects on cancer
formation, which depend on other genetic factors or environmen-
tal exposures. The small sample size plus other confounding fac-
tors like age, gender, diet and lifestyle may attribute to such
differences.
The contradictory findings among different case-control studies
might be attributed to different sample size, source of controls,
genotyping method and matching criteria of subjects. In addition,
the potential gene-gene and gene-environment interactions may
also play vital roles in the pathogenesis.5. Conclusion
In conclusion, this case-control study in Kashmiri subjects
shows that a C to T variation (Arg to Trp) of DNA repair gene XRCC1
is not associated with the risk of developing skin cancer, suggesting
that the variant genotype of XRCC1 at codon 194 may not play a
major role in the etiology of skin cancer. However, statistical anal-
ysis of the combined homozygous and heterozygous variants of
each codon showed a relatively higher risk of developing skin can-
cer and the individual 194Trp allele also showed a borderline sig-
nificance. This discrepancy can be attributed to relatively small
sample size analyzed in the study. To the best of our knowledge,
this is the first report on this XRCC1 Arg194Trp polymorphism in
a Kashmiri population. This association warrants further study in
larger population.Conflict of interest
Authors declare no conflict of interest.
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